Hummingbird Bio Closes $125 Million Financing for Precision Medical Candidates

Singapore 's Hummingbird Bioscience closed a $125 million Series C financing round led by Novo Holdings. The company is developing novel precision candidates by focusing on difficult-to-drug targets that have been biologically validated in cancer and autoimmune disease. Hummingbird has developed a platform based on a data-driven systems biology approach, which engineers next-gen therapies for unmet needs. It has announced three candidates, two of which have started clinical trials, one for HER3 cancers and another for advanced solid tumors. More details.... Share this with colleagues: // //